SomaLogic and Novartis sign ten-year proteomics agreement

SomaLogic has entered into a new ten-year agreement with Novartis to expand the use of its SomaScan proteomic platform across Novartis's drug development, including analysis of at least 250,000 clinical samples.

“SomaLogic, Inc., announced today that it has entered into a new ten-year agreement with its long-time pharmaceutical partner, Novartis, to expand the application of SomaLogic’s leading proteomic technology across the company’s drug discovery and development efforts.”globenewswire.com

• 1 source
• globenewswire.comSomaLogic Significantly Expands Key StrategicSomaLogic, Inc.Oct 21, 2019

Summarized from public sources; check the original articles before acting on it.